Empagliflozin is a sodium-glucose cotransporter 2 inhibitor that has been approved for the treatment of T2D in adults in the EU, US, and Japan due to its high selectivity [2]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.